Development of the Commercial Manufacturing Process for Nirmatrelvir in 17 Months

[Image: see text] The advancement of nirmatrelvir, the active ingredient in Paxlovid, from discovery to emergency use authorization was achieved in just 17 months, requiring an unprecedented rate of chemical process development.

Detalles Bibliográficos
Autores principales: Allais, Christophe, Connor, Christina G., Do, Nga M., Kulkarni, Samir, Lee, Johnny W., Lee, Taegyo, McInturff, Emma, Piper, Jared, Place, Dave W., Ragan, John A., Weekly, R. Matt
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2023
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10069651/
https://www.ncbi.nlm.nih.gov/pubmed/37252346
http://dx.doi.org/10.1021/acscentsci.3c00145

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10069651/
https://www.ncbi.nlm.nih.gov/pubmed/37252346
http://dx.doi.org/10.1021/acscentsci.3c00145

Ejemplares similares